Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum adipocytokine levels in patients with renal cell carcinoma.

Endokrynologia Polska·2026
Same author

Lipidogram profiles in patients with Graves' and Basedow's disease with and without orbitopathy.

Endokrynologia Polska·2026
Same author

Is vitamin D deficiency a risk factor for obesity-related morbidity, prediabetes, and type 2 diabetes - a literature review and proposals from the experts of the Polish Society of Endocrinology.

Endokrynologia Polska·2025
Same author

Sarcoidosis unmasked by Cushing's syndrome: successful surgical resolution.

Archives of medical science : AMS·2025
Same author

The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy.

Endokrynologia Polska·2025
Same author

Adrenal tumours and subclinical adrenal hyperfunction.

Endokrynologia Polska·2025

Related Experiment Video

Updated: Jun 28, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

[Subclinical hypothyroidism].

Robert Krysiak1, Bogdan Marek, Bogusław Okopień

  • 1Kliniki Chorób Wewnetrznych i Farmakologii Klinicznej Katedry Farmakologii w Katowicach. r.krysiak@poczta.onet.pl

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|October 23, 2008
PubMed
Summary

Subclinical hypothyroidism, characterized by high thyroid stimulating hormone (TSH) with normal thyroid hormones, may cause subtle symptoms and risks. Treatment decisions for mild cases should be individualized, with thyroxine therapy recommended for TSH levels above 10 mIU/L.

Related Experiment Videos

Last Updated: Jun 28, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Area of Science:

  • Endocrinology
  • Internal Medicine

Context:

  • Subclinical hypothyroidism is a common endocrine disorder.
  • Characterized by elevated serum thyroid stimulating hormone (TSH) with normal free thyroid hormone levels.
  • May represent mild tissue hypothyroidism, not just pituitary compensation.

Purpose:

  • To review the epidemiology, etiopathogenesis, clinical presentation, diagnosis, and management of subclinical hypothyroidism.
  • To provide evidence-based screening and treatment recommendations.
  • To highlight potential risks associated with subclinical hypothyroidism.

Summary:

  • Subclinical hypothyroidism presents with elevated TSH and normal thyroid hormones, potentially leading to subtle symptoms, lipoprotein abnormalities, atherosclerosis, cardiac dysfunction, and neuropsychiatric effects.
  • While screening is recommended, evidence for treatment benefits is insufficient.
  • Thyroxine therapy is advised for TSH > 10 mIU/L; lower levels require individualized assessment.

Impact:

  • Informs clinical practice regarding the careful screening of subclinical hypothyroidism.
  • Guides individualized treatment decisions based on TSH levels and patient factors.
  • Raises awareness of potential cardiovascular and neuropsychiatric risks associated with this condition.